New shot in the arm for tough lymphomas: simpler treatment tested
NCT ID NCT06504394
Summary
This study is testing a new, under-the-skin version of an immunotherapy drug (pembrolizumab) for adults whose Hodgkin lymphoma or a related B-cell lymphoma has come back or not responded to prior treatments. The main goals are to see how the drug behaves in the body when given this way, how well it shrinks tumors, and how safe it is. It involves about 66 participants and is currently active but not recruiting new volunteers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ankara Universitesi Tıp Fakultesi Hastanesi ( Site 0801)
Ankara, 06100, Turkey (Türkiye)
-
Auckland City Hospital ( Site 1001)
Auckland, 1023, New Zealand
-
Biocenter ( Site 0203)
Concepción, Región del Biobío, 4070196, Chile
-
Bradfordhill-Clinical Area ( Site 0202)
Santiago, Region M. de Santiago, 8420383, Chile
-
Centro de Investigacion Clinica de Oaxaca ( Site 0405)
Oaxaca City, 68020, Mexico
-
Churchill Hospital ( Site 0604)
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
Clinical Research Alliance ( Site 0101)
Westbury, New York, 11590, United States
-
Clínica Inmunocel ( Site 0201)
Santiago, Region M. de Santiago, 7580206, Chile
-
Comprehensive Cancer Centers of Nevada ( Site 0114)
Las Vegas, Nevada, 89169, United States
-
FALP ( Site 0207)
Santiago, Region M. de Santiago, 7500921, Chile
-
Glan Clwyd Hospital ( Site 0602)
Bodelwyddan, Denbighshire, LL18 5UJ, United Kingdom
-
Hacettepe Universite Hastaneleri ( Site 0802)
Ankara, 06230, Turkey (Türkiye)
-
Health Pharma Professional Research S.A. de C.V: ( Site 0403)
Mexico City, Mexico City, 03100, Mexico
-
Hospital Universitario 12 de Octubre-Hemathology and hemotherapy ( Site 0701)
Madrid, 28041, Spain
-
Hospital Universitario de Salamanca ( Site 0702)
Salamanca, Castille and León, 37007, Spain
-
IC La Serena Research ( Site 0204)
La Serena, Coquimbo Region, 1720430, Chile
-
Institut Català d'Oncologia - L'Hospitalet-Haematology Department ( Site 0703)
L'Hospitalet Del Llobregat, Barcelona, 08908, Spain
-
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0504)
Gliwice, Silesian Voivodeship, 44-102, Poland
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 0501)
Warsaw, Masovian Voivodeship, 02-781, Poland
-
Ondokuz Mayıs Universitesi ( Site 0803)
Samsun, 55270, Turkey (Türkiye)
-
Pratia MCM Krakow ( Site 0503)
Krakow, Lesser Poland Voivodeship, 30-727, Poland
-
Seoul National University Hospital-Oncology ( Site 1101)
Seoul, 03080, South Korea
-
The Christie NHS Foundation Trust ( Site 0603)
Manchester, m20 4bx, United Kingdom
-
Universitaetsklinikum Essen ( Site 1302)
Essen, North Rhine-Westphalia, 45147, Germany
-
University College London Hospital ( Site 0605)
London, London, City of, NW1 2PG, United Kingdom
-
University of Iowa - Waukee ( Site 0111)
Waukee, Iowa, 50263, United States
-
University of Iowa-Holden Comprehensive Cancer Center ( Site 0115)
Iowa City, Iowa, 52242, United States
-
Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0502)
Gdansk, Pomeranian Voivodeship, 80-214, Poland
-
Westmead Hospital ( Site 0901)
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.